Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia: A Pediatric Oncology Group study

P. D. Sadowitz, R. Dubowy, A. Souid, Bradley H Pollock, H. Weinstein, R. T. Parmley, W. P. Bowman, V. Land, T. Vats, C. Pratt, G. R. Buchanan

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Purpose: The purpose of this phase I study was to determine the toxicities and response to continuous infusion carboplatin in combination with a fixed dose of etoposide (VP-16) in children with refractory acute leukemia. Patients and Methods: From January 1989 to February 1992, 20 patients received 28 courses of treatment. Each course of treatment consisted of a 1- hour intravenous (IV) infusion of VP-16 100 mg/m2/d for 5 days, followed by a 23-hour IV infusion of carboplatin each day. The initial, total 5-day dose of carboplatin (1,000 mg/m2) was escalated by 250- to 375-mg increments to a final, total dose of 1,875 mg/m2 over 5 days. Results: Significant marrow suppression was observed in all patients, with prolonged marrow aplasia at the 1,875-mg/m2 dose level. Grade III diarrhea occurred in three patients; 10 patients experienced life-threatening infection and three had severe thrombocytopenic bleeding. Major marrow responses (two complete remissions and two partial remissions) occurred in four patients (20%). Conclusion: In view of the apparent antileukemic efficacy and minimal extramedullary toxicity, carboplatin deserves further study in a phase II trial.

Original languageEnglish (US)
Pages (from-to)1969-1973
Number of pages5
JournalJournal of Clinical Oncology
Volume12
Issue number9
StatePublished - Sep 1994
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sadowitz, P. D., Dubowy, R., Souid, A., Pollock, B. H., Weinstein, H., Parmley, R. T., Bowman, W. P., Land, V., Vats, T., Pratt, C., & Buchanan, G. R. (1994). Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia: A Pediatric Oncology Group study. Journal of Clinical Oncology, 12(9), 1969-1973.